1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)

Technology appraisal [TA674] Published date: 17 February 2021

  • Guidance
  • Tools and resources
  • Evidence

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Other supporting evidence  
  • MSD Cancer Drugs Fund termination engagement meeting presentation PDF 1.06 MB 17 February 2021  
  • Cancer Drugs Fund termination engagement meeting (slide set) PowerPoint 457.77 KB 17 February 2021  
  • Public Health England's data review on pembrolizumab for treating urothelial cancer PDF 501.45 KB 17 February 2021